Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice

Title: Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice
Authors: Desjardins, Cody A; Yao, Monica; Hall, John; O’Donnell, Emma; Venkatesan, Reshmii; Spring, Sean; Wen, Aiyun; Hsia, Nelson; Shen, Peiyi; Russo, Ryan; Lan, Bo; Picariello, Tyler; Tang, Kim; Weeden, Timothy; Zanotti, Stefano; Subramanian, Romesh; Ibraghimov-Beskrovnaya, Oxana
Contributors: Dyne Therapeutics, Inc
Source: Nucleic Acids Research ; volume 50, issue 20, page 11401-11414 ; ISSN 0305-1048 1362-4962
Publisher Information: Oxford University Press (OUP)
Publication Year: 2022
Description: Current therapies for Duchenne muscular dystrophy (DMD) use phosphorodiamidate morpholino oligomers (PMO) to induce exon skipping in the dystrophin pre-mRNA, enabling the translation of a shortened but functional dystrophin protein. This strategy has been hampered by insufficient delivery of PMO to cardiac and skeletal muscle. To overcome these limitations, we developed the FORCETM platform consisting of an antigen-binding fragment, which binds the transferrin receptor 1, conjugated to an oligonucleotide. We demonstrate that a single dose of the mouse-specific FORCE–M23D conjugate enhances muscle delivery of exon skipping PMO (M23D) in mdx mice, achieving dose-dependent and robust exon skipping and durable dystrophin restoration. FORCE–M23D-induced dystrophin expression reached peaks of 51%, 72%, 62%, 90% and 77%, of wild-type levels in quadriceps, tibialis anterior, gastrocnemius, diaphragm, and heart, respectively, with a single 30 mg/kg PMO-equivalent dose. The shortened dystrophin localized to the sarcolemma, indicating expression of a functional protein. Conversely, a single 30 mg/kg dose of unconjugated M23D displayed poor muscle delivery resulting in marginal levels of exon skipping and dystrophin expression. Importantly, FORCE–M23D treatment resulted in improved functional outcomes compared with administration of unconjugated M23D. Our results suggest that FORCE conjugates are a potentially effective approach for the treatment of DMD.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/nar/gkac641
Availability: https://doi.org/10.1093/nar/gkac641; https://academic.oup.com/nar/article-pdf/50/20/11401/47609232/gkac641.pdf
Rights: https://creativecommons.org/licenses/by-nc/4.0/
Accession Number: edsbas.52488658
Database: BASE